Navigation Links
Rx for Africa, Inc. Now Trading Under New Symbol (RXAF.PK)
Date:10/31/2007

NEW YORK, Oct. 31 /PRNewswire-FirstCall/ -- Rx for Africa, Inc. (Other OTC: RXAF.PK), announced today that effective immediately, its stock will now trade under the symbol RXAF.PK and that the name "Diamond Entertainment" and its symbol (DMON.PK) will no longer be used as part of the company's operations.

Rx for Africa, Inc. is the surviving company in a reverse merger completed in May 2007 with Diamond Entertainment Corp. - (DMON.PK). Through its wholly owned subsidiary, Rx Africa (Ethiopia) PLC (formerly known as Sunshine Pharmaceutical), Rx for Africa, Inc. owns and operates a state-of-the art pharmaceutical plant built on twenty three thousand square meters of land located south of Addis Ababa, Ethiopia. The Company is currently producing and marketing eight generic products in Ethiopia, with the goal of increasing production within the next 12 to 18 months to 50 products meeting US Food and Drug Administration (US FDA) and World Health Organization (WHO) good manufacturing practices (GMP). The expected product list includes three malaria drugs, three drugs for tuberculosis, nine HIV drugs, 27 antibiotics, and several each of anti-protozoans, anti-fungals and anti-emetics.

"The change in our name and symbol to Rx Africa, Inc. (RXAF.PK) better reflects our mission and focus as a world-class provider of generic medicines, including those for HIV/AIDS, malaria, tuberculosis and other diseases," commented Dr. Mulugetta Bezzabeh, CEO of Rx Africa (Ethiopia) PLC and board member of Rx for Africa, Inc. "Though presently focused solely in Ethiopia, we plan to expand our distribution throughout sub-Saharan Africa and beyond, and our new name and symbol are properly reflective of our path and vision. We are going to be a major player in the African pharmaceutical business."

For further information contact:

Howard Becker, Director

Rx for Africa, Inc.

(917) 553-1205

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners or others that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.


'/>"/>
SOURCE Rx for Africa, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
2. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
3. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
4. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
5. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
6. Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the American Association of Cancer Research Annual Meeting in Los Angeles
7. Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for INO-1001 at ACC Demonstrating PARP Inhibition and Anti-inflammatory Activity in Plasma of Patients Undergoing Primary Percutaneous Coronary Intervention
8. MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study of Aquavan Injection in Patients Undergoing Bronchoscopy
9. Use of Sequenoms MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
Breaking Medicine Technology:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
Breaking Medicine News(10 mins):